Ionis Pharmaceuticals Net Income
| IONS Stock | USD 82.67 1.21 1.44% |
As of the 3rd of February, Ionis Pharmaceuticals retains the Downside Deviation of 1.85, market risk adjusted performance of (0.83), and Risk Adjusted Performance of 0.083. Ionis Pharmaceuticals technical analysis makes it possible for you to employ historical prices and volume momentum with the intention to determine a pattern that calculates the direction of the firm's future prices. Please check out Ionis Pharmaceuticals coefficient of variation, maximum drawdown, as well as the relationship between the Maximum Drawdown and skewness to decide if Ionis Pharmaceuticals is priced fairly, providing market reflects its last-minute price of 82.67 per share. Given that Ionis Pharmaceuticals has jensen alpha of 0.2092, we strongly advise you to confirm Ionis Pharmaceuticals's regular market performance to make sure the company can sustain itself at a future point.
Ionis Pharmaceuticals Total Revenue |
|
Gross Profit | Profit Margin | Market Capitalization | Enterprise Value Revenue 13.2744 | Revenue |
| Last Reported | Projected for Next Year | ||
| Net Loss | -408.5 M | -388.1 M | |
| Net Loss | -408.5 M | -388.1 M | |
| Net Loss | -242.7 M | -230.6 M | |
| Net Loss | (2.73) | (2.60) | |
| Net Income Per E B T | 0.89 | 0.93 |
Ionis | Net Income | Build AI portfolio with Ionis Stock |
The evolution of Net Income for Ionis Pharmaceuticals provides essential context for understanding the company's financial health trajectory. By analyzing this metric's behavior over time, investors can assess whether recent trends align with long-term patterns, and how Ionis Pharmaceuticals compares to historical norms and industry peers.
Latest Ionis Pharmaceuticals' Net Income Growth Pattern
Below is the plot of the Net Income of Ionis Pharmaceuticals over the last few years. Net income is one of the most important fundamental items in finance. It plays a large role in Ionis Pharmaceuticals financial statement analysis. It represents the amount of money remaining after all of Ionis Pharmaceuticals operating expenses, interest, taxes and preferred stock dividends have been deducted from a company total revenue. It is Ionis Pharmaceuticals' Net Loss historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Ionis Pharmaceuticals' overall financial position and show how it may be relating to other accounts over time.
| View | Last Reported (453.9 M) | 10 Years Trend |
|
Net Income |
| Timeline |
Ionis Net Income Regression Statistics
| Arithmetic Mean | (133,132,073) | |
| Geometric Mean | 88,463,174 | |
| Coefficient Of Variation | (174.19) | |
| Mean Deviation | 185,259,035 | |
| Median | (84,801,000) | |
| Standard Deviation | 231,901,301 | |
| Sample Variance | 53778.2T | |
| Range | 781M | |
| R-Value | (0.56) | |
| Mean Square Error | 39538.8T | |
| R-Squared | 0.31 | |
| Significance | 0.02 | |
| Slope | (25,599,183) | |
| Total Sum of Squares | 860451.4T |
Ionis Net Income History
Other Fundumenentals of Ionis Pharmaceuticals
| Net Income From Continuing Ops | ||
| Net Income Applicable To Common Shares | ||
| Net Income Per Share | ||
| Net Income Per E B T |
Ionis Pharmaceuticals Net Income component correlations
Ionis Net Income Driver Correlations
Understanding the fundamental principles of building solid financial models for Ionis Pharmaceuticals is extremely important. It helps to project a fair market value of Ionis Stock properly, considering its historical fundamentals such as Net Income. Since Ionis Pharmaceuticals' main accounts across its financial reports are all linked and dependent on each other, it is essential to analyze all possible correlations between related accounts. However, instead of reviewing all of Ionis Pharmaceuticals' historical financial statements, investors can examine the correlated drivers to determine its overall health. This can be effectively done using a conventional correlation matrix of Ionis Pharmaceuticals' interrelated accounts and indicators.
Click cells to compare fundamentals
Is there potential for Biotechnology market expansion? Will Ionis introduce new products? Factors like these will boost the valuation of Ionis Pharmaceuticals. Market participants price Ionis higher when confident in its future expansion prospects. Understanding fair value requires weighing current performance against future potential. All the valuation information about Ionis Pharmaceuticals listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth (0.44) | Earnings Share (1.59) | Revenue Per Share | Quarterly Revenue Growth 0.171 | Return On Assets |
Understanding Ionis Pharmaceuticals requires distinguishing between market price and book value, where the latter reflects Ionis's accounting equity. The concept of intrinsic value—what Ionis Pharmaceuticals' is actually worth based on fundamentals - guides informed investors toward better entry and exit points. Analysts utilize numerous techniques to assess fundamental value, seeking to purchase shares when trading prices fall beneath estimated intrinsic worth. Market sentiment, economic cycles, and investor behavior can push Ionis Pharmaceuticals' price substantially above or below its fundamental value.
Please note, there is a significant difference between Ionis Pharmaceuticals' value and its price as these two are different measures arrived at by different means. Investors typically determine if Ionis Pharmaceuticals is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. In contrast, Ionis Pharmaceuticals' trading price reflects the actual exchange value where willing buyers and sellers reach mutual agreement.
Ionis Pharmaceuticals 'What if' Analysis
In the world of financial modeling, what-if analysis is part of sensitivity analysis performed to test how changes in assumptions impact individual outputs in a model. When applied to Ionis Pharmaceuticals' stock what-if analysis refers to the analyzing how the change in your past investing horizon will affect the profitability against the current market value of Ionis Pharmaceuticals.
| 11/05/2025 |
| 02/03/2026 |
If you would invest 0.00 in Ionis Pharmaceuticals on November 5, 2025 and sell it all today you would earn a total of 0.00 from holding Ionis Pharmaceuticals or generate 0.0% return on investment in Ionis Pharmaceuticals over 90 days. Ionis Pharmaceuticals is related to or competes with Ascendis Pharma, BridgeBio Pharma, Revolution Medicines, Roivant Sciences, Summit Therapeutics, Biomarin Pharmaceutical, and Exelixis. Ionis Pharmaceuticals, Inc. discovers and develops RNA-targeted therapeutics in the United States More
Ionis Pharmaceuticals Upside/Downside Indicators
Understanding different market momentum indicators often help investors to time their next move. Potential upside and downside technical ratios enable traders to measure Ionis Pharmaceuticals' stock current market value against overall market sentiment and can be a good tool during both bulling and bearish trends. Here we outline some of the essential indicators to assess Ionis Pharmaceuticals upside and downside potential and time the market with a certain degree of confidence.
| Downside Deviation | 1.85 | |||
| Information Ratio | 0.0766 | |||
| Maximum Drawdown | 8.64 | |||
| Value At Risk | (2.67) | |||
| Potential Upside | 3.19 |
Ionis Pharmaceuticals Market Risk Indicators
Today, many novice investors tend to focus exclusively on investment returns with little concern for Ionis Pharmaceuticals' investment risk. Other traders do consider volatility but use just one or two very conventional indicators such as Ionis Pharmaceuticals' standard deviation. In reality, there are many statistical measures that can use Ionis Pharmaceuticals historical prices to predict the future Ionis Pharmaceuticals' volatility.| Risk Adjusted Performance | 0.083 | |||
| Jensen Alpha | 0.2092 | |||
| Total Risk Alpha | 0.0741 | |||
| Sortino Ratio | 0.0826 | |||
| Treynor Ratio | (0.84) |
Ionis Pharmaceuticals February 3, 2026 Technical Indicators
| Cycle Indicators | ||
| Math Operators | ||
| Math Transform | ||
| Momentum Indicators | ||
| Overlap Studies | ||
| Pattern Recognition | ||
| Price Transform | ||
| Statistic Functions | ||
| Volatility Indicators | ||
| Volume Indicators |
| Risk Adjusted Performance | 0.083 | |||
| Market Risk Adjusted Performance | (0.83) | |||
| Mean Deviation | 1.61 | |||
| Semi Deviation | 1.65 | |||
| Downside Deviation | 1.85 | |||
| Coefficient Of Variation | 955.67 | |||
| Standard Deviation | 1.99 | |||
| Variance | 3.97 | |||
| Information Ratio | 0.0766 | |||
| Jensen Alpha | 0.2092 | |||
| Total Risk Alpha | 0.0741 | |||
| Sortino Ratio | 0.0826 | |||
| Treynor Ratio | (0.84) | |||
| Maximum Drawdown | 8.64 | |||
| Value At Risk | (2.67) | |||
| Potential Upside | 3.19 | |||
| Downside Variance | 3.41 | |||
| Semi Variance | 2.73 | |||
| Expected Short fall | (1.81) | |||
| Skewness | (0.09) | |||
| Kurtosis | (0.09) |
Ionis Pharmaceuticals Backtested Returns
Currently, Ionis Pharmaceuticals is very steady. Ionis Pharmaceuticals holds Efficiency (Sharpe) Ratio of 0.0949, which attests that the entity had a 0.0949 % return per unit of risk over the last 3 months. We have found thirty technical indicators for Ionis Pharmaceuticals, which you can use to evaluate the volatility of the firm. Please check out Ionis Pharmaceuticals' Market Risk Adjusted Performance of (0.83), downside deviation of 1.85, and Risk Adjusted Performance of 0.083 to validate if the risk estimate we provide is consistent with the expected return of 0.19%. Ionis Pharmaceuticals has a performance score of 7 on a scale of 0 to 100. The company retains a Market Volatility (i.e., Beta) of -0.24, which attests to not very significant fluctuations relative to the market. As returns on the market increase, returns on owning Ionis Pharmaceuticals are expected to decrease at a much lower rate. During the bear market, Ionis Pharmaceuticals is likely to outperform the market. Ionis Pharmaceuticals right now retains a risk of 1.99%. Please check out Ionis Pharmaceuticals maximum drawdown, as well as the relationship between the skewness and day typical price , to decide if Ionis Pharmaceuticals will be following its current trending patterns.
Auto-correlation | -0.07 |
Very weak reverse predictability
Ionis Pharmaceuticals has very weak reverse predictability. Overlapping area represents the amount of predictability between Ionis Pharmaceuticals time series from 5th of November 2025 to 20th of December 2025 and 20th of December 2025 to 3rd of February 2026. The more autocorrelation exist between current time interval and its lagged values, the more accurately you can make projection about the future pattern of Ionis Pharmaceuticals price movement. The serial correlation of -0.07 indicates that barely 7.0% of current Ionis Pharmaceuticals price fluctuation can be explain by its past prices.
| Correlation Coefficient | -0.07 | |
| Spearman Rank Test | 0.08 | |
| Residual Average | 0.0 | |
| Price Variance | 3.21 |
Because income is reported on the Income Statement of a company and is measured in dollars some investors prefer to use Profit Margin, which measures income as a percentage of sales.
| Competition |
Ionis Accumulated Other Comprehensive Income
Accumulated Other Comprehensive Income |
|
Based on the recorded statements, Ionis Pharmaceuticals reported net income of (453.9 Million). This is 233.0% lower than that of the Biotechnology sector and significantly lower than that of the Health Care industry. The net income for all United States stocks is 179.49% higher than that of the company.
Ionis Net Income Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Ionis Pharmaceuticals' direct or indirect competition against its Net Income to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Ionis Pharmaceuticals could also be used in its relative valuation, which is a method of valuing Ionis Pharmaceuticals by comparing valuation metrics of similar companies.Ionis Pharmaceuticals is currently under evaluation in net income category among its peers.
Ionis Pharmaceuticals ESG Sustainability
Some studies have found that companies with high sustainability scores are getting higher valuations than competitors with lower social-engagement activities. While most ESG disclosures are voluntary and do not directly affect the long term financial condition, Ionis Pharmaceuticals' sustainability indicators can be used to identify proper investment strategies using environmental, social, and governance scores that are crucial to Ionis Pharmaceuticals' managers, analysts, and investors.Environmental | Governance | Social |
Ionis Pharmaceuticals Institutional Holders
Institutional Holdings refers to the ownership stake in Ionis Pharmaceuticals that is held by large financial organizations, pension funds or endowments. Institutions may hold large blocks of Ionis Pharmaceuticals' outstanding shares and can exert considerable influence upon its management. Institutional holders may also work to push the share price higher once they own the stock. Extensive social media coverage, TV shows, articles in high-profile magazines, and presentations at investor conferences help move the stock higher, increasing Ionis Pharmaceuticals' value.| Shares | Tweedy, Browne Co Llc | 2025-06-30 | 2.9 M | Geode Capital Management, Llc | 2025-06-30 | 2.9 M | Two Sigma Advisers, Llc | 2025-06-30 | 2.7 M | Millennium Management Llc | 2025-06-30 | 2.6 M | Bvf Inc | 2025-06-30 | 1.9 M | Two Sigma Investments Llc | 2025-06-30 | 1.8 M | Ubs Group Ag | 2025-06-30 | 1.5 M | Citadel Advisors Llc | 2025-06-30 | 1.5 M | Charles Schwab Investment Management Inc | 2025-06-30 | 1.5 M | Fmr Inc | 2025-06-30 | 23.6 M | Vanguard Group Inc | 2025-06-30 | 16.7 M |
Ionis Fundamentals
| Return On Equity | -0.4 | ||||
| Return On Asset | -0.0568 | ||||
| Profit Margin | (0.27) % | ||||
| Operating Margin | (1.02) % | ||||
| Current Valuation | 12.84 B | ||||
| Shares Outstanding | 161.97 M | ||||
| Shares Owned By Insiders | 0.62 % | ||||
| Shares Owned By Institutions | 99.38 % | ||||
| Number Of Shares Shorted | 13.73 M | ||||
| Price To Earning | 101.16 X | ||||
| Price To Book | 21.99 X | ||||
| Price To Sales | 13.85 X | ||||
| Revenue | 705.14 M | ||||
| Gross Profit | 73.71 M | ||||
| EBITDA | (353.72 M) | ||||
| Net Income | (453.9 M) | ||||
| Cash And Equivalents | 2.04 B | ||||
| Cash Per Share | 14.36 X | ||||
| Total Debt | 1.42 B | ||||
| Debt To Equity | 2.00 % | ||||
| Current Ratio | 8.18 X | ||||
| Book Value Per Share | 3.83 X | ||||
| Cash Flow From Operations | (500.95 M) | ||||
| Short Ratio | 7.45 X | ||||
| Earnings Per Share | (1.59) X | ||||
| Price To Earnings To Growth | 25.70 X | ||||
| Target Price | 90.67 | ||||
| Number Of Employees | 1.07 K | ||||
| Beta | 0.31 | ||||
| Market Capitalization | 13.39 B | ||||
| Total Asset | 3 B | ||||
| Retained Earnings | (2.25 B) | ||||
| Working Capital | 2.31 B | ||||
| Current Asset | 837 M | ||||
| Current Liabilities | 148.88 M | ||||
| Net Asset | 3 B |
About Ionis Pharmaceuticals Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Ionis Pharmaceuticals's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Ionis Pharmaceuticals using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Ionis Pharmaceuticals based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Thematic Opportunities
Explore Investment Opportunities
Additional Tools for Ionis Stock Analysis
When running Ionis Pharmaceuticals' price analysis, check to measure Ionis Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Ionis Pharmaceuticals is operating at the current time. Most of Ionis Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Ionis Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Ionis Pharmaceuticals' price. Additionally, you may evaluate how the addition of Ionis Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.